GetTopicDetailResponse(id=e429269e448, topicName=侯金林, introduction=侯金林, content=null, image=null, comments=1, allHits=976, url=https://h5.medsci.cn/topic?id=26974, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=12462, tagList=[TagDto(tagId=12462, tagName=侯金林)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2240891, encodeId=48c4224089184, content=<a href='/topic/show?id=e429269e448' target=_blank style='color:#2F92EE;'>#侯金林#</a>、<a href='/topic/show?id=a78c4996069' target=_blank style='color:#2F92EE;'>#張文宏#</a>團隊發(fā)現(xiàn)<a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'>#乙肝#</a>新藥<a href='/topic/show?id=32f8121890c2' target=_blank style='color:#2F92EE;'>#Xalnesiran#</a>大幅度提高表面抗原轉(zhuǎn)陰率（Piranga研究）
這個研究意義重大，應(yīng)該能進入2024年度<a href='/topic/show?id=ae41356995a' target=_blank style='color:#2F92EE;'>#十大#</a>研究進展。, objectTitle=NEJM：侯金林、張文宏團隊發(fā)現(xiàn)乙肝新藥Xalnesiran大幅度提高表面抗原轉(zhuǎn)陰率（Piranga研究）, objectType=article, longId=853875, objectId=efec8538e5bb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241101/7a717836deaf424dbe04d314827a881d-L9vfek9sGUjJ.jpg, objectUrl=/article/show_article.do?id=efec8538e5bb, replyNumber=0, likeNumber=69, createdTime=2024-12-05, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=efec8538e5bb, moduleTitle=NEJM：侯金林、張文宏團隊發(fā)現(xiàn)乙肝新藥Xalnesiran大幅度提高表面抗原轉(zhuǎn)陰率（Piranga研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=efec8538e5bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
